Clinical Trials Logo
  1. Home
  2. Newly Diagnosed Multiple Myeloma
  3. NCT01936532

Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) — IFM2013-06  

Newly Diagnosed Multiple Myeloma Clinical Trial

Official title:
Phase II Trial Studying the Efficacy of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone as Induction Prior to, and as Consolidation After High-dose Therapy With Peripheral Stem Cell Transplantation Followed by MLN9708 Maintenance in the Initial Management of Multiple Myeloma in Patients Younger Than 66 Years

Clinical Trial Summary

This is a phase II, multicenter, open-label study to evaluate the safety and efficacy of MLN9708 in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed multiple myeloma. The patient population will consist of adult men and women younger than 66 years, who have a confirmed diagnosis of MM who meet eligibility criteria. Following the screening period, patients will be enrolled and treated then, they will receive induction therapy (3 cycles), a systematic Peripheral Blood Stem Cell harvest. After Peripheral Blood Stem Cell Transplantation, patient will enter in the consolidation phase (early and late one) 2 months after transplantation. Finally, patients follow a Maintenance therapy (start 1 month after the last cycle of consolidation) during 12 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01936532
Study type Interventional
Source Nantes University Hospital
Contact
Status Completed
Phase Phase 2
Start date November 12, 2014
Completion date June 4, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04052880 - Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM Phase 2
Active, not recruiting NCT03742297 - Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years Phase 3
Not yet recruiting NCT05558319 - NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide Phase 3
Recruiting NCT04891809 - Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM Phase 2
Not yet recruiting NCT05561049 - Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma
Recruiting NCT05259553 - Biomarkers in Multiple Myeloma N/A
Completed NCT01809717 - Multiple Myeloma and Exercise N/A
Withdrawn NCT04348006 - Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Phase 4
Terminated NCT03733691 - Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients Phase 2
Active, not recruiting NCT00405756 - A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. Phase 3
Recruiting NCT05665140 - Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients Phase 2/Phase 3
Not yet recruiting NCT05088330 - A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM N/A
Active, not recruiting NCT03948035 - Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM Phase 3
Not yet recruiting NCT06348147 - Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation Phase 2
Recruiting NCT06324266 - Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation Phase 2/Phase 3